|
|
||||||||
1From the Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, University Clinics Tübingen, Germany; the 2University Eye Hospital, Centre for Ophthalmology, University Clinics Tübingen, Germany; 3The Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Denmark; the 4University Eye Hospital, Munich, Germany; the 5Department of Medical Genetics, Institute for Human Genetics, University Tübingen, Germany; and the 6Gordon Norrie Centre for Genetic Eye Diseases, Kennedy Institute–National Eye Clinic, Hellerup, Denmark.
| Abstract |
|---|
|
|
|---|
METHODS. Seventeen patients from 13 families underwent a detailed ophthalmic examination including color vision testing, Goldmann visual fields, fundus photography, Ganzfeld and multifocal ERGs, and optical coherence tomography. The coding sequences and flanking intron/UTR sequences of PDE6C and KCNV2 were screened for mutations by means of DHPLC and direct DNA sequencing of PCR-amplified genomic DNA.
RESULTS. Whereas no mutations were detected in the PDE6H gene, mutations in KCNV2 were identified in all patients, in either the homozygous or compound heterozygous state. Ten of the 11 identified mutations were novel, including three missense and six truncating mutations and one gross deletion. The mutations concordantly segregate in all available families according a recessive mode of inheritance. The CDSRR phenotype was associated with reduced visual acuity of variable degree and color vision defects. Macular defects ranging from mild pigmentary changes to distinct foveal atrophy were present in nine patients. Progression of the disease was observed in only three of seven patients with follow-up data.
CONCLUSIONS. The phenotype of cone dystrophy with supernormal rod response is tightly linked with mutations in KCNV2.
Since its initial description in 1983,1 several subsequent case series have been published with essentially similar clinical findings.2 3 4 5 6 7 The pathomechanism of CDSRR has been disputed controversially in the literature. Because of the similarities with electrophysiological recordings in experimental model systems, notably from cat eyes perfused with IBMX, a potent phosphodiesterase inhibitor, it has been suggested that CDSRR may be caused by a defect of cGMP metabolism in photoreceptors.1 3 8 However, thorough investigations of the ERG responses of patients with CDSRR led Hood et al.6 to conclude a pathology distal to the outer segment and most likely occurring at the level of the first synapse.
Although the reported case series on CDSRR suggest an autosomal recessive mode of inheritance, the genetic basis of this disorder remained elusive until very lately. A recent report by Piri et al.9 seemed to nourish the cGMP metabolism hypothesis. They described a patient with CDSRR who carried a nucleotide substitution in the 5' untranslated sequence of PDE6H, encoding the inhibitory
-subunit of the cone phosphodiesterase. Functional analysis showed that this mutation increases PDE6H synthesis in vitro. However, doubts remained because this result did not match the expected recessive mode of inheritance and because the unaffected father also carried the mutation.
Only recently, Wu et al.10 applied a whole-genome autozygosity mapping approach in a large inbred sibship that enabled them to map a locus for CDSRR on chromosome 9p24. Subsequent candidate gene analysis in that region led to the identification of mutations in KCNV2 in that family and in additional independent patients with CDSRR.
Here we report an independent study to evaluate the prior genetic findings, based on a sample of 17 patients with CDSRR from 13 independent families. In addition, we compiled and compared the clinical data of those patients.
| Materials and Methods |
|---|
|
|
|---|
Patients underwent a standard ophthalmic examination, including evaluation of eye movements, visual acuity (VA), refraction, slit lamp, and fundus examination including fundus photography. Photopic visual field measurements were performed with a Goldmann perimeter (Haag-Streit AG, Bern, Switzerland) using objects I/4e and IV/4e. Color vision screening was performed with Ishihara 38 plates edition 1986, Farnsworth-Munsell D-15 standard and desaturated, Lanthonys Tritan album (LTA), American Optical Hand-Hardy-Rittler (AOHRR), and Nagels anomaloscope (Schmidt-Haensch, Berlin) were used to classify the anomaly.
Dark adaptation was measured with a Goldmann-Weekers instrument (Haag-Streit AG) according to the instruction manual for the integral examination of the whole retina or with the Tübingen Hand Perimeter at 20° eccentricity of the nasal hemifield.
Full-field ERG and multifocal ERG recordings were performed in accordance with the ISCEV recommendations. Optical coherence tomography (OCT) scans were obtained with a Stratus OCT (Carl Zeiss Meditec AG, Jena, Germany). Statistical calculations of mean VAs and confidence intervals (CI) were performed with log(VA) to achieve a perceptual metric.
Patients with CDSRR recruited for this study were selected based on pathognomonic ERG findings including (1) reduced b-wave amplitudes and prolonged implicit times in dark-adapted ERG recordings with low-intensity flashes, (2) elevated b-wave amplitudes and prolonged implicit times in dark-adapted ERG recordings with high-intensity flashes, and (3) reduced amplitudes and prolonged implicit time in single-flash light-adapted and/or flicker ERG recordings.
The study was performed according to the tenets of the Declaration of Helsinki, and all participants gave written consent.
Molecular Genetic Analysis
DNA was isolated from peripheral blood according to standard procedures. DNA fragments were amplified from genomic DNA by means of PCR. PCR fragments covering exons 1 to 4 and flanking intron and UTR sequences of PDE6H (see Table 1 for primer sequences) were analyzed by denaturing high-performance liquid chromatography (WAVE 3500HT system; Transgenomic Inc., Omaha, NE). The resulting trace profiles were examined with proprietary software (Navigator program; Transgenomics) and compared with the profile of wild-type DNA fragments. Samples with aberrant profiles were sequenced as follows: PCR fragments were subjected to a clean-up protocol (ExoSAP-IT; GE Healthcare, Freiburg, Germany) and then to direct DNA sequencing with dye-termination chemistry (BigDye Terminator ver. 1.1; Applied Biosystems [ABI], Darmstadt, Germany). All sequences were run on a capillary sequencer (ABI 3100; ABI) and analyzed with proprietary sequence trace analysis (Sequence Analysis, ver. 5.1; ABI) or sequence trace alignment software (SeqMan; DNASTAR, Madison, WI).
|
Genotyping of the V2_STR marker (Table 1) was performed by PCR amplification followed by separation on a 12% nondenaturing PAA gel and silver staining.11
Quantitative analysis of KCNV2 DNA copy number was done by real-time PCR employing TaqMan technology. Primers KCNV2_TQF and KCNV2-TQR were used to amplify an 81-bp fragment (corresponding to c.424—c.504) of exon 1 of the KCNV2 gene and real-time quantitative analysis was done by inclusion of a self designed TaqMan probe KCNV2-TQ (see Table 1 for oligonucleotide sequences). 25 µL reactions containing 12.5 µL 2x Master Mix (TaqMan Universal Master Mix; ABI), 900 nM of each PCR primer, 250 nM of the KCNV2-TQ probe, and 10 ng of genomic DNA were amplified applying the recommended cycling program with 2 min at 50°C, 10 min at 95°C and 40 cycles of 15 s at 95°C and 1 min at 60°C on a real-time PCR cycler (ABI 7500 instrument). In parallel, we performed real-time PCR reactions for a human genome single-copy reference sequence (TaqMan RNase P Control Reagent Kit; ABI). Real-time PCRs were performed in triplicate and mean Ct was used for the calculations. The mean of the
Ct (CtKCNV2 – CtRNaseP) of four control samples were used as calibrator and 
Ct and 2–
Ct were calculated for the samples to be assessed.
| Results |
|---|
|
|
|---|
Screening of the KCNV2 Gene
Wu et al.10 recently reported mutations in KCNV2 in patients with CDSRR. We therefore sequenced the whole coding sequence and flanking intron and UTR sequences of the KCNV2 gene in all 13 index patients of our sample. We were able to identify either homozygous or two heterozygous mutations in every patient. These mutations include five nonsense mutations (p.E73X, p.Q76X, p.E148X, p.K260X, and p.Q287X), a 9-bp in-frame deletion (p.D339_V341del), a gross deletion of parts of the KCNV2 gene, a 1-bp insertion that results in a frameshift and premature translation termination (p.K120fsX371), and three missense mutations (p.E184K, p.E184V, and p.G461R) (Table 2) . The latter were found to be evolutionary highly conserved in KCNV2 channels of various species as well as in the whole family of six transmembrane helices Kv channels. Both the SIFT (provided by the Fred Hutchinson Cancer Research Center, Seattle, WA)12 and Polyphen (provided by the Division of Genetics, Brigham and Womens Hospital, Harvard Medical School, Boston, MA)13 programs predicted these substitutions to be deleterious for protein function. Except for the 9-bp in-frame deletion that has been reported by Wu et al.,10 all other mutations were new. All new point mutations were excluded in >100 (n = 105–115) independent normal Danish control subjects. Cosegregation analysis was performed in 11 families comprising 30 family members. In two families, there was one additional affected sibling, and in one family there were another three affected family members. In all three families, we were able to confirm that the affected siblings share the same two mutant alleles. In contrast, none of the available unaffected siblings (n = 6) showed the same allele combination as their affected sib.
|
|
Clinical Findings in Patients with KCNV2 Mutations
The clinical data of 16 patients (13 index patients and 3 affected siblings) are summarized in Table 4 . The age at examination varied between 2 and 61 years and the observation period from 0 to 24 years. All patients showed ERGs typical of CDSRR (see the Material and Methods section and Fig. 1 ). Multifocal ERG recordings obtained from patient SR exhibited a loss of responses in the center, whereas more peripheral locations yielded significant responses, yet with reduced amplitudes and prolonged implicit times (Figs. 1B 1C) .
|
|
|
| Discussion |
|---|
|
|
|---|
Piri et al.9 recently identified a nucleotide substitution in the 5' UTR of the PDE6H gene in a single CDSRR family that induces an increase in PDE6H expression in vitro. However, the presence of mutations in PDE6H as a cause of CDSRR was not replicated in either the study by Wu et al.10 or in our sample. Therefore we doubt that mutations in PDE6H cause CDSRR. Otherwise such mutations must be very rare.
In a recent study, the gene locus for CDSRR has been mapped to 9p24 by means of autozygosity mapping in a large consanguineous family and subsequently mutations in KCNV2 were identified in this family as well as in several independent patients.10 Our data confirm these findings and prove that KCNV2 is the major gene mutated in CDSRR. Notably, we were able to identify KCNV2 mutations in all our patients. The patients were either homozygous for a KCNV2 mutation or carried two compound heterozygous mutations. Concordant segregation results were obtained in all 11 families in which samples from additional family members (n = 30) were available. Moreover, all new point mutations were excluded in a representative sample of Danish controls. Six of the identified mutations are either nonsense mutations or cause a translational frameshift that results in truncated or largely altered proteins lacking important functional domains of KCNV2, notably several transmembrane helices and the channel pore. Moreover, those mutant transcripts may undergo nonsense-mediated mRNA decay before actually being translated. Thus these mutations most likely represent functionally null alleles in the cellular context. In addition, we identified a gross deletion that includes at least a large proportion of the first of the two exons of KCNV2.
Three mutations cause missense substitutions that affect amino acid positions that are highly conserved in evolution and are located in functionally important domains. E184 is located at the outermost position of the N-terminal A- and B-box domain that controls the subfamily-specific tetramerization of heterooligomeric Kv channels.14 We found E184 to be affected in two distinct mutations that substitute this residue by lysine or valine, respectively, suggesting that E184 represents a functionally very important amino acid at this position. The third missense mutation, G461R, affects the third residue of the ultraconserved -GYG- tripeptide motif that functions as an ion selectivity filter in the pore of Kv channels.15 Notably, Wu et al.10 have reported a missense mutation of the first glycine in this very tripeptide.
In our study, we identified altogether 11 different mutations. Ten of these represent new mutations, whereas only the D339_Val341del mutation had been identified in the prior study. The K120fs and the E148X mutations were each present on five mutant alleles and the G461R on six. In total, these three mutations account for more than 60% of all mutant alleles in our patients. The absence of these mutations in the mixed sample of Wu et al.10 may indicate that they represent founder mutations in the Danish population to which most of the patients belonged.
The clinical data are in accordance with earlier descriptions of the disease.1 2 3 4 5 6 7 The clinical symptoms are rather unremarkable, and unless ERG examinations are routinely applied to cases with a moderate unexplained visual deficiency, the diagnosis will pass unnoticed. The relatively few cases published worldwide compared with the relative high number of diagnosed cases in the small Danish population (5.5 million inhabitants) may indicate that the disorder is widely underdiagnosed. A possible effect from a few Danish founders may also be involved.
Phenotype–genotype correlations were difficult to address because of the allelic heterogeneity and the various allelic combinations in compound heterozygotes. Comparing affected siblings that share identical mutation genotypes, we found a prominent difference in VAs between subjects NN and CN, with NN being one with the worst acuity (0.08/0.05) and CN being one with the best (0.5/0.3). The four affected siblings in family ZD184 who are homozygous for the Q76X mutation (three of them listed in Table 4 ) had rather uniform VAs that ranged between 0.08 and 0.2. Yet only two of these siblings showed fundus irregularities. It is conceivable that in recessive conditions missense mutations may cause a less severe phenotype than protein-truncating mutations. The missense mutation G461R is the only frequent missense mutation in our sample that is amenable for testing such a hypothesis. When correlating VAs of patients with this mutation with VAs of patients carrying two nonsense alleles (stop or frameshift mutations) we found a mean VA of 0.215 (95% CI: 0.14–0.331) in subjects carrying the G461R (12 eyes) in comparison with a mean VA of 0.117 (95% CI: 0.086–0.16) in subjects carrying two nonsense alleles (18 eyes). These data indicate that the G461R missense mutation may in fact be functionally less severe than protein-truncating mutations. We also noted that all progressive cases in our sample were patients carrying protein-truncating mutations: one patient homozygous for the mutation E148X and two unrelated patients homozygous for K120fs. Nonetheless, larger patient series and follow-up studies are needed to substantiate this observation.
KCNV2 encodes a modulatory, electrophysiologically silent subunit of the family of voltage-gated potassium channels now called Kv8.2.16 In vitro Kv8.2 is able to assemble functional heterotetramers with primary potassium channel subunits such as Kv2.1 and Kv3.1. Such heteromeric Kv2.1/Kv8.2 channels show slightly altered electrophysiological properties compared with Kv2.1 homomers.16
Expression analysis detected highest levels of KCNV2 transcripts in pancreas and testis and weaker expression in lung, liver, kidney, spleen, thymus, prostate, and ovary.16 In the context of its association with CDSRR, Wu et al.10 studied KCNV2 expression in the human retina and found its expression to be restricted to the outer retina. Preliminary results from an ongoing study applying single-cell PCR experiments in the mouse retina indicate that KCNV2 is predominantly expressed in rod photoreceptors (Koeppen K, Ladewig T, unpublished data, 2007). The identity of the primary potassium channel subunit expected to assemble with Kv8.2 in photoreceptors still remains to be established. Various studies and our own data showed that, except for KCNA7, all genes encoding primary potassium channel subunits from groups A–D are expressed in the retina17 18 and transcripts for Kv1.2 to 1.6 and Kv3.3 are present in photoreceptor preparations (Koeppen K, Ladewig T, unpublished data, 2007).
Voltage-gated potassium channels have a wide range of functions, including control of duration and frequency of action potentials and the regulation of the resting membrane potential. The latter is probably the predominant function of potassium channels in photoreceptors. It has been reported that voltage-gated potassium channels found in rods limit the amplitude of spike depolarization.19 20 Conversely, blocking voltage-gated potassium channels, which decreases membrane conductance and increases rod excitability, always induces spontaneous calcium spikes, thus evoking regenerative potentials.21
Further research is needed to clarify the actual role of KCNV2 in photoreceptor response and retinal physiology.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication April 20, 2007; revised September 24, 2007; accepted December 12, 2007.
Disclosure: B. Wissinger, None; S. Dangel, None; H. Jägle, None; L. Hansen, None; B. Baumann, None; G. Rudolph, None; C. Wolf, None; M. Bonin, None; K. Koeppen, None; T. Ladewig, None; S. Kohl, None; E. Zrenner, None; T. Rosenberg, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Bernd Wissinger, Molecular Genetics Laboratory, Centre for Ophthalmology, University Clinics Tübingen, Röntgenweg 11, D-72076 Tübingen, Germany; wissinger{at}uni-tuebingen.de.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |